Patient characteristics at baseline (T0) and retest visit (T1).
| Characteristics | T0, n = 68 | T1, n = 39 | Characteristics, T1 vs T0, P |
|---|---|---|---|
| Sex, male | 39 (57) | 25 (64) | NS |
| Private healthcare, % | 29 (43) | 16 (41) | NS |
| Age, yrs | 44 ± 12 | ||
| Employed | 44 (65) | ||
| Chronic sick leave due to SpA | 13 (19) | ||
| Current smoker | 17 (25) | ||
| Disease durationa, yrs | 11 (6–22) | ||
| HLA-B27–positiveb,d | 33 (49) | ||
| Extraaxial manifestations | 49 (72) | ||
| Psoriasis | 24 (35) | ||
| Anterior uveitis | 22 (32) | ||
| Inflammatory bowel disease | 7 (10) | ||
| History of peripheral arthritis | 34 (50) | ||
| Current treatment | |||
| Conventional DMARD | 32 (47) | ||
| NSAID | 43 (63) | ||
| Biologics | 27 (40) | ||
| Corticosteroids | 16 (24) | ||
| Physical examination | |||
| Tender joint(s) at study visit | 29 (43) | ||
| Enthesitis (MASES) score | 3 (0–7) | ||
| BASMI linear score | 3.6 (2.8–4.8) | 3.6 ± 1.5 | NS |
| Laboratory examination | |||
| CRP, mg/l, n = 42 | 4 (1–13) | ||
| ESR, mm/h, n = 41 | 23 (10–34) | ||
| Patient-reported disease variables | |||
| Patient global disease, NRS | 5.0 ± 2.6 | 4.7 ± 2.3 | NS |
| ASDAS score, n = 47 | 3.1 ± 1.2 | 2.6 ± 1.0 | NS |
| BASDAI, NRS | 5.0 ± 2.5 | 4.3 ± 2.3 | 0.01 |
| High disease activityc | 46 (68) | 21 (54) | NS |
| BASFI, NRS | 4.1 ± 2.8 | 4.0 ± 2.5 | NS |
Values are reported as numbers (%), mean (± SD), or median (IQR).
↵a Years with symptoms.
↵b 24 (35%) HLA-B27–negative, 11 (16%) unknown.
↵c ASDAS ≥ 2.1 or if unavailable, BASDAI ≥ 4.
↵d Background prevalence of HLA-B27 in Chile is 2–3%. AS: ankylosing spondylitis; ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; BASMI: Bath Ankylosing Spondylitis Metrology Index; CRP: C-reactive protein; DMARD: disease-modifying antirheumatic drug; ESR: erythrocyte sedimentation rate; MASES: Maastricht Ankylosing Spondylitis Enthesitis Score; NRS: numerical rating scale; NS: not significant; NSAID: nonsteroidal antiinflammatory drug; SpA: spondyloarthritis.